PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study
Open Access
- 16 January 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (1), 72
- https://doi.org/10.3390/pharmaceutics12010072
Abstract
The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood–brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang–2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system.Keywords
Funding Information
- Ministero degli Affari Esteri e della Cooperazione Internazionale (PI Tosi, Nanomedicine for BBB-crossing in CNS oncologic pathologies)
- Innovative Medicines Initiative (No 807015)
This publication has 33 references indexed in Scilit:
- LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's diseaseFrontiers in Physiology, 2012
- Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's diseaseInternational Journal of Pharmaceutics, 2011
- Nanoparticle PEGylation for Imaging and TherapyNanomedicine, 2011
- Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain gliomaBiomaterials, 2011
- Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistributionJournal of Controlled Release, 2010
- Poly(ethylene glycol)-block-poly(d,l-lactide acid) micelles anchored with angiopep-2 for brain-targeting deliveryJournal of Drug Targeting, 2010
- Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimerBiomaterials, 2009
- Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2Journal of Neurochemistry, 2008
- Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123Journal of Controlled Release, 2007
- Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrierJournal of Controlled Release, 2005